Fridkin, Mati

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases

Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B. H., & Fridkin, M. (2005) · Bioorganic & Medicinal Chemistry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 278

Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 185

Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease1

Avramovich‐Tirosh, Y., Amit, T., Bar‐Am, O., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2007) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 130

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., & Zheng, H. (2005) · Mechanisms of Ageing and Development

Cholinesterase and Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments

Cited by 128

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., & Zheng, H. (2004) · Journal of Neural Transmission

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 123

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease

Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006) · Parkinson’s Disease and Related Disorders

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 58

Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons

Zheng, H., Youdim, M. B. H., Weiner, L. M., & Fridkin, M. (2005) · Biochemical Pharmacology

Neuroprotection in Cerebral IschemiaParkinson's Disease Mechanisms and Treatments

Cited by 53